Apollo Group ties up with Credence Genomics | Sunday Observer

Apollo Group ties up with Credence Genomics

Chennai, November 15: The Apollo Hospitals Group, India’s largest integrated healthcare provider announced the launch of a portfolio of cutting edge diagnostics services for infectious diseases. The new line of tests are being offered in partnership with Credence Genomics, and are based on a specialized DNA diagnostics platform offering faster and more precise diagnosis.

Through this partnership, Credence Genomics’ flagship products – the Rapid Infection Detection (RID), Bactfast and Fungifast will now be readily available to benefit patients and assist the medical fraternity in India by offering fast and precise diagnosis for infectious diseases.

Vice Chairperson, Apollo Hospitals Group, Dr. Preetha Reddy said, “It has been our constant endeavor to ensure the most superior technology-based clinical solutions are made available to our patients.

“Through the introduction of this service portfolio, patients will benefit immensely through faster and more accurate diagnosis for infectious diseases. Bacterial and fungal infectious diseases take a great toll on populations of the sub-continent.”

Founding CEO and Director, Credence Genomics Dr. Vaz Gnanam said, “We join hands with the Apollo Group in delivering the highest standards in healthcare in total alignment to their global credibility and brand promise.” The diagnostic products Credence RID, Bactfast and Fungifast are diagnostic tests which can diagnose any infectious disease caused by a bacteria or fungi with over 90% accuracy.

As part of the collaborations Credence Genomics will set up a state-of-the-art DNA research/diagnostics facility in Chennai.